Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study
G. Bilger, Nicolas Girard, H. Doubre, Matteo Giaj Levra, Etienne Giroux‐Leprieur, Frédérique Giraud, C. Decroisette, Matthieu Carton, Marie Ange Massiani
Topics & Concepts
DiscontinuationMedicineInternal medicineRetrospective cohort studyProgressive diseaseLung cancerSurgerynon-small cell lung cancer (NSCLC)GastroenterologyDiseaseA549 cellCancer Immunotherapy and BiomarkersLung Cancer Research StudiesLung Cancer Treatments and Mutations